Johnson & Johnson to acquire eye‑disease biotech Ollin Biosciences for up to $3.3 billion
Johnson & Johnson announced on 16 Nov 2026 that it will buy Texas‑based Ollin Biosciences. The deal includes a $2.2 billion cash upfront payment and milestone payments that could bring total consideration to roughly $3.3 billion. Ollin’s lead candidate, the bispecific antibody OLN324, is in Phase III trials for wet age‑related macular degeneration and diabetic macular oedema. The transaction is expected to close before the end of 2026, subject to regulatory approval.
Why it matters
The acquisition expands J&J’s ophthalmology pipeline and adds a late‑stage asset that could diversify revenue beyond its existing anti‑VEGF drugs. The deal’s size, confirmed at up to $3.3 billion, may affect J&J’s cash balance and could influence analyst earnings forecasts for the coming year.
Key facts
- 1J&J agreed on 16 Nov 2026 to acquire Ollin Biosciences financial-news.co.uk
- 2The transaction includes a $2.2 billion upfront cash payment financial-news.co.uk
- 3Milestone payments are capped at roughly $1.125 billion, bringing total consideration to up to $3.3 billion financial-news.co.uk
- 4Earlier reports cited a total deal value of up to $3.4 billion finance.yahoo.com
- 5The deal is expected to close before the end of 2026, subject to regulatory clearance financial-news.co.uk
- 6Ollin’s lead drug OLN324 is a bispecific antibody in Phase III for wet AMD and diabetic macular oedema pharmaceutical-technology.com
Open questions
- Total headline value differs between $3.4 billion (early reports) and $3.3 billion (company‑disclosed terms)
- Milestone amount reported as $1.2 billion in some early articles versus $1.125 billion in the confirmed terms
Summary written by AlphAI AI Desk from 10 of 10 sources. Not investment advice. Figures are as stated by the linked sources.